Spots Global Cancer Trial Database for Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Official Title: An Open-label, Single-arm, Phase 2 Study Of Inotuzumab Ozogamicin Plus Rituximab In Subjects With Relapsed/Refractory Cd22-positive Diffuse Large B-cell Lymphoma, Eligible For Autologous Stem Cell Transplantation
Study ID: NCT00867087
Conditions
Study Description
Brief Summary: The purpose of this study is to evaluate inotuzumab ozogamicin in combination with rituximab prior to an autologous stem cell transplant (aSCT) in patients with relapsed/refractory diffuse large B-cell Non-Hodgkin's lymphoma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Loyola University Medical Center, Foster G. McGraw Hospital and Satellites, Maywood, Illinois, United States
Tufts Medical Center, Boston, Massachusetts, United States
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Barnes-Jewish Hospital, Saint Louis, Missouri, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Siteman Cancer Center, Saint Peters, Missouri, United States
John Theurer Cancer Center (JTCC) at Hackensack University Medical Center (HUMC), Hackensack, New Jersey, United States
John Theurer Cancer Center (JTCC) at Hackensack University Medical Center (HUMC), Hackensack, New Jersey, United States
Hackensack University Medical CenteR, Hackensack, New Jersey, United States
John Theurer Cancer Center (JTCC) at Hackensack University Medical Center (HUMC), Hackensack, New Jersey, United States
John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
Memorial Sloan - Kettering Cancer Center, New York, New York, United States
Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
UT Southwestern University Hospital - St. Paul, Dallas, Texas, United States
Zale Lipshy University Hospital, Dallas, Texas, United States
UT Southwestern Medical Center, Dallas, Texas, United States
The University of Texas, M. D. Anderson Cancer Center, Houston, Texas, United States
University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
Methodist Healthcare System of, San Antonio, Texas, United States
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Pharmaceutical Research Center, Madison, Wisconsin, United States
CHRU de Lille Hopital Claude Huriez, Lille, , France
Institut Paoli Calmettes, Marseille, , France
CHU Saint-Eloi, Montpellier Cedex 5, , France
Hopital Saint Louis, Paris, , France
Hopital Haut-Leveque, Pessac, , France
CH Lyon Sud, Pierre-Benite cedex 114, , France
CH Lyon Sud, Pierre-benite Cedex, , France
Departement d'Hematologie et d'Oncologie-, Strasbourg, , France
Charite Campus Virchow-Kilinikum-, Berlin, , Germany
Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of
Asan Medical Center, Seoul, Seoul/korea, Korea, Republic of
Severance Hospital, Yonsei University Health System, Seoul, , Korea, Republic of
Singapore General Hospital, Singapore, , Singapore
Christie Hospital, Manchester, , United Kingdom
The Christie NHS Foundation Trust, Manchester, , United Kingdom
Contact Details
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
